查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1859227

过继性细胞免疫疗法市场报告：趋势、预测和竞争分析（至2031年）

Adoptive Cellular Immunotherapy Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球过继性细胞免疫疗法市场前景广阔，在医院、癌症研究机构及其他市场均蕴藏着巨大机会。预计2025年至2031年间，全球过继性细胞免疫疗法市场将以23.1%的复合年增长率成长。推动该市场成长的关键因素包括：癌症发生率的不断上升带动了对过继性细胞免疫疗法的需求；细胞疗法的进步提高了治疗效果和预后；以及过继性细胞免疫疗法的高昂成本。

  • Lucintel预测，在预测期内，CAR-T细胞疗法将是所有治疗类型中成长最快的。
  • 按最终用途划分，预计医院将实现最高成长。
  • 从区域来看，预计亚太地区在预测期内将达到最高成长。

过继性细胞免疫疗法市场的新趋势

过继性细胞免疫疗法市场正在经历几个新兴趋势，这反映了细胞疗法不断扩大的潜力、改善患者预后以及扩大治疗范围。

  • 拓展至固体癌：儘管CAR-T疗法在血液肿瘤治疗中取得了巨大成功，但人们对将其应用拓展至固体癌的兴趣日益浓厚。 CAR-T细胞标靶机制和修饰技术的进步，使得CAR-T细胞在治疗乳癌、肺癌和卵巢等癌症方面更有效。这种拓展是重要的发展趋势，将扩大过继性细胞疗法的影响范围。
  • 个人化和精准医疗：过继性细胞疗法正成为个人化医疗的重要组成部分，其治疗方案根据患者的个别基因谱量身定制。客製化治疗，例如开发患者特异性CAR-T细胞，能够提高治疗效果并改善预后。这一趋势正在革新癌症治疗，为患者提供高度标靶和个人化的选择。
  • 联合治疗：人们越来越关注将过继性细胞免疫疗法与其他治疗方法，例如免疫查核点抑制剂、化疗和标靶治疗。这种策略旨在增强免疫反应、克服抗药性机制并提高整体疗效。联合治疗有望成为提高过继性细胞免疫疗法在多种癌症治疗中成功率的重要驱动因素。
  • 监管进展与核准：美国、中国和日本等主要市场的监管机构正在加速核准过继性细胞免疫疗法，尤其是CAR-T疗法。简化核准流程缩短了疗法上市时间，使患者能够更快地获得治疗。这些进展对于加速CAR-T疗法的应用和推动市场成长至关重要。
  • 降低成本和提高可及性：过继性细胞免疫疗法的高昂价格一直是其面临的主要挑战。然而，目前各方正努力降低生产成本、提高扩充性并开发更经济实惠的治疗方法。降低生产成本将提高可及性，使更多患者，特别是印度和中国等开发中国家，能够获得这些先进治疗方法。

过继性细胞免疫疗法市场正在涌现许多新兴趋势，包括拓展至固体癌、个人化医疗、联合治疗、不断变化的监管环境以及成本降低，这些趋势正在重塑癌症治疗格局。这些趋势提升了过继性细胞疗法为全球癌症患者提供更有效、更容易取得且更具针对性的治疗方案的潜力。

近期过继性细胞免疫疗法市场趋势

受技术创新、新的临床试验结果和监管部门核准，过继性细胞免疫疗法市场正经历显着的发展。这些进展正在扩大过继性细胞疗法的应用范围，并提高其在治疗各种癌症方面的疗效。

  • FDA核准的CAR-T疗法：在美国，Kymriah和Yescarta等CAR-T疗法已核准用于治疗白血病和淋巴瘤等血液癌症。这些核准为CAR-T疗法进一步拓展至固体癌铺平了道路。这些治疗方法的成功推动了CAR-T细胞疗法的应用，标誌着免疫疗法市场的重大进展。
  • CAR-T细胞生产技术的进步：CAR-T细胞生产技术的创新正在提高生产的规模化能力、成本效益和速度。新的自动化技术有助于降低生产成本，从而解决过继性细胞免疫疗法面临的关键挑战之一。更有效率的生产将增加CAR-T疗法的供应，使全球更多患者能够获得这些治疗。
  • 临床试验的扩展：过继性细胞免疫疗法的临床试验正在包括美国、中国和印度在内的多个国家迅速扩展。这些试验正在探索新的适应症和治疗方法组合，使研究人员能够评估 CAR-T 和 TIL 疗法在更广泛癌症类型中的疗效。试验数量的增加是推动市场成长和创新的关键因素。
  • 新兴市场的监管核准：中国和日本等国家已简化了过继性细胞疗法的监管核准流程，这正在加速这些地区的市场成长。监管机构正与生物技术公司密切合作，以确保创新治疗方法的快速引入，从而增加CAR-T疗法的可及性并扩大其市场。
  • 生物技术-製药策略联盟：生技公司与大型製药企业之间的合作正在加速过继性细胞免疫疗法的开发和商业化。这些联盟能够共用资源、研究和专业知识，这对推进CAR-T细胞疗法和其他细胞疗法的临床开发至关重要。这些联盟在拓展市场方面发挥关键作用。

近年来，过继性细胞免疫疗法市场取得了一系列进展，包括获得FDA核准、技术创新、扩大临床试验规模、获得监管机构核准以及建立战略合作伙伴关係，这些都推动了市场成长。这些进展使更多患者能够受益于过继性细胞疗法，并有望彻底改变癌症治疗模式。

目录

第一章执行摘要

第二章 市场概览

  • 背景和分类
  • 供应链

第三章：市场趋势与预测分析

  • 产业驱动因素与挑战
  • PESTLE分析
  • 专利分析
  • 法规环境

第四章 全球过继性细胞免疫疗法市场（按类型划分）

  • 概述
  • 吸引力分析：按类型
  • CAR-T细胞疗法：趋势与预测（2019-2031）
  • NK细胞疗法：趋势与预测（2019-2031）
  • TIL疗法：趋势与预测（2019-2031）
  • 其他：趋势与预测（2019-2031 年）

5. 全球过继性细胞免疫疗法市场（依最终用途划分）

  • 概述
  • 吸引力分析：依最终用途划分
  • 医院：趋势与预测（2019-2031）
  • 癌症研究所：趋势与预测（2019-2031）
  • 其他：趋势与预测（2019-2031 年）

第六章 区域分析

  • 概述
  • 全球过继性细胞免疫疗法市场（按地区划分）

7. 北美过继性细胞免疫疗法市场

  • 概述
  • 北美过继性细胞免疫疗法市场（按类型划分）
  • 北美过继性细胞免疫疗法市场依最终用途划分
  • 美国过继性细胞免疫疗法市场
  • 墨西哥过继性细胞免疫疗法市场
  • 加拿大过继性细胞免疫疗法市场

8. 欧洲过继性细胞免疫疗法市场

  • 概述
  • 欧洲过继性细胞免疫疗法市场（按类型划分）
  • 欧洲过继性细胞免疫疗法市场依最终用途划分
  • 德国过继性细胞免疫疗法市场
  • 法国过继性细胞免疫疗法市场
  • 西班牙过继性细胞免疫疗法市场
  • 义大利过继性细胞免疫疗法市场
  • 英国过继性细胞免疫疗法市场

9. 亚太地区过继性细胞免疫疗法市场

  • 概述
  • 亚太地区过继细胞免疫疗法市场（按类型划分）
  • 亚太地区过继性细胞免疫疗法市场（依最终用途划分）
  • 日本的过继性细胞免疫疗法市场
  • 印度过继性细胞免疫疗法市场
  • 中国细胞免疫疗法市场
  • 韩国过继性细胞免疫疗法市场
  • 印尼过继性细胞免疫疗法市场

10. 世界其他地区（ROW）过继性细胞免疫疗法市场

  • 概述
  • ROW过继细胞免疫疗法市场按类型划分
  • ROW过继细胞免疫疗法市场以最终用途划分
  • 中东过继性细胞免疫疗法市场
  • 南美洲过继性细胞免疫疗法市场
  • 非洲过继性细胞免疫疗法市场

第十一章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析
    • 竞争对手之间的竞争
    • 买方议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 新进入者的威胁
  • 市占率分析

第十二章：机会与策略分析

  • 价值链分析
  • 成长机会分析
    • 按类型分類的成长机会
    • 按最终用途分類的成长机会
  • 全球过继性细胞免疫疗法市场的新趋势
  • 战略分析
    • 新产品开发
    • 认证和许可
    • 企业合併、协议、合作关係和合资企业

第十三章：价值链中主要企业的概况

  • 竞争分析
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Gilead Sciences Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA

第十四章附录

  • 图表清单
  • 表格列表
  • 分析方法
  • 免责声明
  • 版权
  • 简称和技术单位
  • 关于 Lucintel
  • 询问

The future of the global adoptive cellular immunotherapy market looks promising with opportunities in the hospitals, cancer institutes, and others markets. The global adoptive cellular immunotherapy market is expected to grow with a CAGR of 23.1% from 2025 to 2031. The major drivers for this market are the growing cancer incidence drives demand for adoptive cellular immunotherapies., the advancements in car-t cell therapies enhance treatment efficacy and outcomes., and the high cost of adoptive cellular immunotherapies.

  • Lucintel forecasts that, within the type category, car t cell therapy is expected to witness the highest growth over the forecast period.
  • Within the application category, hospitals is expected to witness the highest growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Adoptive Cellular Immunotherapy Market

The market for adoptive cellular immunotherapy is witnessing several emerging trends that are reshaping the landscape. These trends reflect the growing potential of cellular therapies, improving patient outcomes, and expanding the scope of treatment.

  • Expansion to Solid Tumors: While CAR-T therapies have shown significant success in hematologic cancers, there is increasing focus on expanding their use to solid tumors. Advances in targeting mechanisms and modifications to CAR-T cells are making them more effective in treating cancers such as breast, lung, and ovarian cancers. This expansion represents a key trend in broadening the impact of adoptive cellular therapies.
  • Personalized and Precision Medicine: Adoptive cellular therapies are becoming an integral part of personalized medicine, where treatments are tailored to the individual genetic profiles of patients. The customization of therapies, including the development of patient-specific CAR-T cells, allows for more effective treatment and improved outcomes. This trend is revolutionizing cancer treatment by offering highly targeted, individualized options for patients.
  • Combination Therapies: There is growing interest in combining adoptive cellular immunotherapy with other treatment modalities, such as immune checkpoint inhibitors, chemotherapy, and targeted therapies. This strategy aims to enhance the immune response, overcome resistance mechanisms, and improve overall treatment efficacy. Combination therapies are expected to be a crucial driver in increasing the success rate of adoptive cellular immunotherapy for diverse cancers.
  • Regulatory Advancements and Approvals: Regulatory bodies in key markets like the U.S., China, and Japan are accelerating the approval of adoptive cellular immunotherapies, especially CAR-T therapies. Streamlined approval processes are reducing the time it takes for therapies to reach the market, facilitating quicker access for patients. This trend is crucial in accelerating the availability of these therapies ly and driving market growth.
  • Cost Reduction and Accessibility: The high cost of adoptive cellular immunotherapies has been a significant challenge. However, efforts to reduce manufacturing costs, improve scalability, and develop more affordable therapies are gaining momentum. As the cost of production decreases, accessibility will improve, making these advanced therapies available to a wider range of patients, particularly in developing countries like India and China.

The emerging trends in the adoptive cellular immunotherapy market, including the expansion to solid tumors, personalized medicine, combination therapies, regulatory advancements, and cost reduction, are reshaping the landscape of cancer treatment. These trends are enhancing the potential for adoptive cellular therapies to offer more effective, accessible, and targeted treatment options for cancer patients worldwide.

Recent Developments in the Adoptive Cellular Immunotherapy Market

The adoptive cellular immunotherapy market has seen significant advancements driven by technological innovations, new clinical trial results, and regulatory approvals. These developments are expanding the scope of adoptive cellular therapies and improving their effectiveness in treating various cancers.

  • FDA-Approved CAR-T Therapies: In the U.S., CAR-T therapies like Kymriah and Yescarta have been approved for the treatment of hematologic cancers such as leukemia and lymphoma. These approvals have paved the way for further expansion into solid tumors. The success of these therapies is driving the adoption of CAR-T cells, making them a key development in the immunotherapy market.
  • Technological Advancements in CAR-T Manufacturing: Innovations in CAR-T cell manufacturing are improving the scalability, cost-effectiveness, and speed of production. New automated technologies are helping reduce production costs, addressing one of the major challenges in adoptive cellular immunotherapy. As manufacturing becomes more efficient, the availability of CAR-T therapies will increase, making these treatments accessible to more patients worldwide.
  • Expansion of Clinical Trials: Clinical trials for adoptive cellular immunotherapies are rapidly expanding across various countries, including the U.S., China, and India. These trials are exploring new indications and combinations of therapies, allowing researchers to assess the efficacy of CAR-T and TIL therapies for a wider range of cancers. The increasing number of trials is a key factor driving market growth and innovation.
  • Regulatory Approvals in Emerging Markets: Countries like China and Japan are streamlining regulatory approval processes for adoptive cellular therapies, which is accelerating the market growth in these regions. Regulatory agencies are working closely with biotech companies to ensure the swift introduction of innovative therapies, improving access to CAR-T treatments and expanding the market ly.
  • Strategic Collaborations Between Biotech and Pharma: Collaborations between biotech firms and large pharmaceutical companies are helping accelerate the development and commercialization of adoptive cellular immunotherapies. These partnerships enable the sharing of resources, research, and expertise, which is crucial in advancing the clinical development of CAR-T and other cellular therapies. Such collaborations are playing a significant role in expanding the market.

Recent developments in the adoptive cellular immunotherapy market, including FDA approvals, technological innovations, expansion of clinical trials, regulatory approvals, and strategic collaborations, are driving the growth of the market. These advancements are bringing adoptive cellular therapies to more patients, with the potential to transform cancer treatment.

Strategic Growth Opportunities in the Adoptive Cellular Immunotherapy Market

The growing demand for adoptive cellular therapies presents significant strategic growth opportunities across various applications. These opportunities are expected to expand the market, enhance treatment options, and improve patient outcomes.

  • Expanding Indications for CAR-T Therapy: One of the major growth opportunities lies in expanding CAR-T therapies to treat solid tumors. Research is ongoing to adapt CAR-T cells to target cancers such as lung, breast, and pancreatic cancer. Success in this area could open up a vast new market for adoptive cellular immunotherapies, revolutionizing cancer treatment.
  • Combination of CAR-T with Other Immunotherapies: The combination of CAR-T therapies with other immunotherapies, such as checkpoint inhibitors or monoclonal antibodies, is a promising growth opportunity. This strategy can potentially enhance the immune response and improve overall treatment efficacy. By addressing treatment resistance and increasing tumor targeting, combination therapies could become a key development in the market.
  • Personalized Immunotherapy Approaches: Personalized medicine, including the use of patient-specific CAR-T therapies, presents significant growth potential. As advancements in genomics and cellular engineering continue, customized treatments tailored to individual patients' genetic profiles will become more prevalent, making adoptive cellular therapies more effective and offering better patient outcomes.
  • Regulatory Expediting in Emerging Markets: Emerging markets like China and India represent significant growth opportunities for adoptive cellular immunotherapy. As these countries streamline regulatory processes and expand access to innovative treatments, biotech companies can tap into large, underserved patient populations. This trend is expected to contribute significantly to market growth.
  • Manufacturing Cost Reduction: Reducing the cost of CAR-T and other cellular therapies is a critical growth opportunity. Innovations in manufacturing processes, such as automation and scale-up techniques, will drive down costs, making these therapies more affordable and accessible to a broader population. Lower costs will drive adoption and increase market size.

Strategic growth opportunities in the adoptive cellular immunotherapy market, including expanding indications, combination therapies, personalized medicine, regulatory progress in emerging markets, and manufacturing cost reduction, are poised to drive market expansion. These opportunities will help transform the landscape of cancer treatment, offering more accessible and effective options for patients ly.

Adoptive Cellular Immunotherapy Market Driver and Challenges

The adoptive cellular immunotherapy market is influenced by a range of technological, economic, and regulatory factors. These drivers and challenges impact the development, adoption, and scalability of adoptive cellular therapies. Understanding these elements is crucial for stakeholders seeking to navigate the complex landscape of adoptive immunotherapies, which show promising potential in treating cancer and other diseases but also face significant barriers.

The factors responsible for driving the Adoptive Cellular Immunotherapy Market include:

1. Advancements in Cell Therapy Technologies: Technological innovations in gene editing, stem cell research, and cell expansion techniques have led to more effective and scalable adoptive cellular therapies. These advancements enable higher success rates and improve patient outcomes, which drives growth in the market.

2. Increasing Cancer Incidence: The growing burden of cancer is a significant driver for adoptive cellular immunotherapies. As more patients seek advanced cancer treatments, the demand for immunotherapies like CAR-T and TIL therapies increases, expanding market opportunities.

3. Rising Investment and Funding in Immunotherapy: Increased investment from both public and private sectors into research, clinical trials, and production facilities is accelerating the development of adoptive cellular therapies. This influx of funding drives innovation and supports the commercialization of these therapies.

4. Shifting Focus Towards Personalized Medicine: There is a growing emphasis on personalized medicine, which tailors treatments to individual patients based on their genetic and molecular profiles. Adoptive cellular immunotherapies, such as CAR-T, are well-suited for this trend, further driving their market demand.

5. Regulatory Approvals and Market Expansion: The growing number of regulatory approvals for adoptive cellular immunotherapies, such as CAR-T, is opening new market avenues. These approvals make these therapies more accessible to patients and stimulate growth within the market.

Challenges in the Adoptive Cellular Immunotherapy Market are:

1. High Treatment Costs: The production of adoptive cellular therapies involves complex, personalized processes, leading to high treatment costs. These expenses can limit access to therapies, particularly in low-income regions, and hinder wider adoption, impacting overall market growth.

2. Manufacturing and Scalability Issues: The current manufacturing process for adoptive cellular therapies is labor-intensive, time-consuming, and difficult to scale. This limits the ability to meet growing patient demand and presents challenges to market expansion.

3. Safety and Efficacy Concerns: Despite positive results, the safety and efficacy of adoptive cellular therapies can vary. Adverse effects, such as cytokine release syndrome and neurotoxicity, as well as inconsistent outcomes, remain a challenge, which can undermine patient confidence and slow market adoption.

The adoptive cellular immunotherapy market is shaped by advancements in technology, growing cancer rates, and increasing funding for research. However, high treatment costs, manufacturing challenges, and concerns about safety and efficacy present significant obstacles. Balancing these drivers and challenges will be key to determining the market's future success and its potential for widespread adoption.

List of Adoptive Cellular Immunotherapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies adoptive cellular immunotherapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the adoptive cellular immunotherapy companies profiled in this report include-

  • Bristol-Myers Squibb Company
  • Novartis AG
  • Gilead Sciences Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA

Adoptive Cellular Immunotherapy Market by Segment

The study includes a forecast for the global adoptive cellular immunotherapy market by type, end use, and region.

Adoptive Cellular Immunotherapy Market by Type [Value from 2019 to 2031]:

  • Car T Cell Therapy
  • Nk Cell Therapy
  • Til Therapy
  • Others

Adoptive Cellular Immunotherapy Market by End Use [Value from 2019 to 2031]:

  • Hospitals
  • Cancer Institutes
  • Others

Adoptive Cellular Immunotherapy Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Adoptive Cellular Immunotherapy Market

The market for adoptive cellular immunotherapy is experiencing rapid growth as this innovative approach continues to transform cancer treatment. By harnessing the power of the immune system, adoptive cellular therapies such as CAR-T and TIL therapies are gaining attention in the fight against various cancers. The United States, China, Germany, India, and Japan are leading advancements in research, clinical trials, and regulatory approvals, shaping the landscape for these therapies.

  • United States: The U.S. remains a leader in adoptive cellular immunotherapy, with CAR-T cell therapies such as Kymriah and Yescarta being FDA-approved for multiple cancers. Ongoing research focuses on overcoming challenges like treatment resistance and expanding applications beyond blood cancers to solid tumors. The high demand for personalized therapies and strong financial investment from biotech and pharmaceutical companies are driving the rapid development of these therapies.
  • China: China is making significant strides in adoptive cellular immunotherapy, especially in the development of CAR-T therapies. Chinese companies are leading in the commercialization of cost-effective therapies for blood cancers and have started conducting clinical trials for solid tumors. Regulatory authorities in China are accelerating approval processes, making the country an emerging market for CAR-T cell therapies, and they are looking to expand to more affordable options for patients.
  • Germany: Germany is at the forefront of adoptive cellular immunotherapy research in Europe. Strong collaborations between academic institutions and pharmaceutical companies have advanced CAR-T and TIL (Tumor-Infiltrating Lymphocyte) therapies, particularly for hematologic cancers. The country's supportive regulatory framework and focus on personalized medicine are accelerating the development of these therapies, with increasing participation in clinical trials and ongoing research to enhance efficacy and minimize side effects.
  • India: India's adoptive cellular immunotherapy market is gaining momentum, especially with an increase in clinical trials for CAR-T therapies. Research institutions and biotech companies are partnering with international firms to expand access to innovative therapies. With a large population of cancer patients, particularly those with blood cancers, India is becoming a significant player in the adoption of CAR-T therapies, though affordability and accessibility remain key challenges.
  • Japan: Japan has been advancing in adoptive cellular immunotherapy, with several clinical trials focused on CAR-T and TIL therapies. Japan's efficient healthcare system and regulatory processes are conducive to the approval and rapid adoption of these therapies. Additionally, collaborations with international biotech companies are facilitating the development of new treatments. Japan is particularly focused on expanding these therapies to treat a wider range of cancers, including solid tumors.

Features of the Global Adoptive Cellular Immunotherapy Market

  • Market Size Estimates: Adoptive cellular immunotherapy market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Adoptive cellular immunotherapy market size by type, end use, and region in terms of value ($B).
  • Regional Analysis: Adoptive cellular immunotherapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, end use, and regions for the adoptive cellular immunotherapy market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the adoptive cellular immunotherapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the adoptive cellular immunotherapy market by type (car t cell therapy, nk cell therapy, til therapy, and others), end use (hospitals, cancer institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Adoptive Cellular Immunotherapy Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 CAR T Cell Therapy: Trends and Forecast (2019-2031)
  • 4.4 NK Cell Therapy: Trends and Forecast (2019-2031)
  • 4.5 TIL Therapy: Trends and Forecast (2019-2031)
  • 4.6 Others: Trends and Forecast (2019-2031)

5. Global Adoptive Cellular Immunotherapy Market by End Use

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by End Use
  • 5.3 Hospitals: Trends and Forecast (2019-2031)
  • 5.4 Cancer Institutes: Trends and Forecast (2019-2031)
  • 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Adoptive Cellular Immunotherapy Market by Region

7. North American Adoptive Cellular Immunotherapy Market

  • 7.1 Overview
  • 7.2 North American Adoptive Cellular Immunotherapy Market by type
  • 7.3 North American Adoptive Cellular Immunotherapy Market by end use
  • 7.4 United States Adoptive Cellular Immunotherapy Market
  • 7.5 Mexican Adoptive Cellular Immunotherapy Market
  • 7.6 Canadian Adoptive Cellular Immunotherapy Market

8. European Adoptive Cellular Immunotherapy Market

  • 8.1 Overview
  • 8.2 European Adoptive Cellular Immunotherapy Market by type
  • 8.3 European Adoptive Cellular Immunotherapy Market by end use
  • 8.4 German Adoptive Cellular Immunotherapy Market
  • 8.5 French Adoptive Cellular Immunotherapy Market
  • 8.6 Spanish Adoptive Cellular Immunotherapy Market
  • 8.7 Italian Adoptive Cellular Immunotherapy Market
  • 8.8 United Kingdom Adoptive Cellular Immunotherapy Market

9. APAC Adoptive Cellular Immunotherapy Market

  • 9.1 Overview
  • 9.2 APAC Adoptive Cellular Immunotherapy Market by type
  • 9.3 APAC Adoptive Cellular Immunotherapy Market by end use
  • 9.4 Japanese Adoptive Cellular Immunotherapy Market
  • 9.5 Indian Adoptive Cellular Immunotherapy Market
  • 9.6 Chinese Adoptive Cellular Immunotherapy Market
  • 9.7 South Korean Adoptive Cellular Immunotherapy Market
  • 9.8 Indonesian Adoptive Cellular Immunotherapy Market

10. ROW Adoptive Cellular Immunotherapy Market

  • 10.1 Overview
  • 10.2 ROW Adoptive Cellular Immunotherapy Market by type
  • 10.3 ROW Adoptive Cellular Immunotherapy Market by end use
  • 10.4 Middle Eastern Adoptive Cellular Immunotherapy Market
  • 10.5 South American Adoptive Cellular Immunotherapy Market
  • 10.6 African Adoptive Cellular Immunotherapy Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by End Use
  • 12.3 Emerging Trends in the Global Adoptive Cellular Immunotherapy Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Bristol-Myers Squibb Company
    • Company Overview
    • Adoptive Cellular Immunotherapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Novartis AG
    • Company Overview
    • Adoptive Cellular Immunotherapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Gilead Sciences Inc.
    • Company Overview
    • Adoptive Cellular Immunotherapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 F. Hoffmann-La Roche Ltd
    • Company Overview
    • Adoptive Cellular Immunotherapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Merck KGaA
    • Company Overview
    • Adoptive Cellular Immunotherapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Adoptive Cellular Immunotherapy Market
  • Figure 2.1: Usage of Adoptive Cellular Immunotherapy Market
  • Figure 2.2: Classification of the Global Adoptive Cellular Immunotherapy Market
  • Figure 2.3: Supply Chain of the Global Adoptive Cellular Immunotherapy Market
  • Figure 3.1: Driver and Challenges of the Adoptive Cellular Immunotherapy Market
  • Figure 3.2: PESTLE Analysis
  • Figure 3.3: Patent Analysis
  • Figure 3.4: Regulatory Environment
  • Figure 4.1: Global Adoptive Cellular Immunotherapy Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Adoptive Cellular Immunotherapy Market ($B) by Type
  • Figure 4.3: Forecast for the Global Adoptive Cellular Immunotherapy Market ($B) by Type
  • Figure 4.4: Trends and Forecast for CAR T Cell Therapy in the Global Adoptive Cellular Immunotherapy Market (2019-2031)
  • Figure 4.5: Trends and Forecast for NK Cell Therapy in the Global Adoptive Cellular Immunotherapy Market (2019-2031)
  • Figure 4.6: Trends and Forecast for TIL Therapy in the Global Adoptive Cellular Immunotherapy Market (2019-2031)
  • Figure 4.7: Trends and Forecast for Others in the Global Adoptive Cellular Immunotherapy Market (2019-2031)
  • Figure 5.1: Global Adoptive Cellular Immunotherapy Market by End Use in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Adoptive Cellular Immunotherapy Market ($B) by End Use
  • Figure 5.3: Forecast for the Global Adoptive Cellular Immunotherapy Market ($B) by End Use
  • Figure 5.4: Trends and Forecast for Hospitals in the Global Adoptive Cellular Immunotherapy Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Cancer Institutes in the Global Adoptive Cellular Immunotherapy Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Others in the Global Adoptive Cellular Immunotherapy Market (2019-2031)
  • Figure 6.1: Trends of the Global Adoptive Cellular Immunotherapy Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Adoptive Cellular Immunotherapy Market ($B) by Region (2025-2031)
  • Figure 7.1: North American Adoptive Cellular Immunotherapy Market by type in 2019, 2024, and 2031
  • Figure 7.2: Trends of the North American Adoptive Cellular Immunotherapy Market ($B) by type (2019-2024)
  • Figure 7.3: Forecast for the North American Adoptive Cellular Immunotherapy Market ($B) by type (2025-2031)
  • Figure 7.4: North American Adoptive Cellular Immunotherapy Market by end use in 2019, 2024, and 2031
  • Figure 7.5: Trends of the North American Adoptive Cellular Immunotherapy Market ($B) by end use (2019-2024)
  • Figure 7.6: Forecast for the North American Adoptive Cellular Immunotherapy Market ($B) by end use (2025-2031)
  • Figure 7.7: Trends and Forecast for the United States Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 7.8: Trends and Forecast for the Mexican Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Canadian Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 8.1: European Adoptive Cellular Immunotherapy Market by type in 2019, 2024, and 2031
  • Figure 8.2: Trends of the European Adoptive Cellular Immunotherapy Market ($B) by type (2019-2024)
  • Figure 8.3: Forecast for the European Adoptive Cellular Immunotherapy Market ($B) by type (2025-2031)
  • Figure 8.4: European Adoptive Cellular Immunotherapy Market by end use in 2019, 2024, and 2031
  • Figure 8.5: Trends of the European Adoptive Cellular Immunotherapy Market ($B) by end use (2019-2024)
  • Figure 8.6: Forecast for the European Adoptive Cellular Immunotherapy Market ($B) by end use (2025-2031)
  • Figure 8.7: Trends and Forecast for the German Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 8.8: Trends and Forecast for the French Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the Spanish Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Italian Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the United Kingdom Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 9.1: APAC Adoptive Cellular Immunotherapy Market by type in 2019, 2024, and 2031
  • Figure 9.2: Trends of the APAC Adoptive Cellular Immunotherapy Market ($B) by type (2019-2024)
  • Figure 9.3: Forecast for the APAC Adoptive Cellular Immunotherapy Market ($B) by type (2025-2031)
  • Figure 9.4: APAC Adoptive Cellular Immunotherapy Market by end use in 2019, 2024, and 2031
  • Figure 9.5: Trends of the APAC Adoptive Cellular Immunotherapy Market ($B) by end use (2019-2024)
  • Figure 9.6: Forecast for the APAC Adoptive Cellular Immunotherapy Market ($B) by end use (2025-2031)
  • Figure 9.7: Trends and Forecast for the Japanese Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 9.8: Trends and Forecast for the Indian Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Chinese Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the South Korean Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the Indonesian Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 10.1: ROW Adoptive Cellular Immunotherapy Market by type in 2019, 2024, and 2031
  • Figure 10.2: Trends of the ROW Adoptive Cellular Immunotherapy Market ($B) by type (2019-2024)
  • Figure 10.3: Forecast for the ROW Adoptive Cellular Immunotherapy Market ($B) by type (2025-2031)
  • Figure 10.4: ROW Adoptive Cellular Immunotherapy Market by end use in 2019, 2024, and 2031
  • Figure 10.5: Trends of the ROW Adoptive Cellular Immunotherapy Market ($B) by end use (2019-2024)
  • Figure 10.6: Forecast for the ROW Adoptive Cellular Immunotherapy Market ($B) by end use (2025-2031)
  • Figure 10.7: Trends and Forecast for the Middle Eastern Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 10.8: Trends and Forecast for the South American Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the African Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Adoptive Cellular Immunotherapy Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Adoptive Cellular Immunotherapy Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Adoptive Cellular Immunotherapy Market by Type
  • Figure 12.2: Growth Opportunities for the Global Adoptive Cellular Immunotherapy Market by End Use
  • Figure 12.3: Growth Opportunities for the Global Adoptive Cellular Immunotherapy Market by Region
  • Figure 12.4: Emerging Trends in the Global Adoptive Cellular Immunotherapy Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Adoptive Cellular Immunotherapy Market by Type and End Use
  • Table 1.2: Attractiveness Analysis for the Adoptive Cellular Immunotherapy Market by Region
  • Table 1.3: Global Adoptive Cellular Immunotherapy Market Parameters and Attributes
  • Table 3.1: Trends of the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 3.2: Forecast for the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Adoptive Cellular Immunotherapy Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 4.4: Trends of CAR T Cell Therapy in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 4.5: Forecast for CAR T Cell Therapy in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 4.6: Trends of NK Cell Therapy in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 4.7: Forecast for NK Cell Therapy in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 4.8: Trends of TIL Therapy in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 4.9: Forecast for TIL Therapy in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 4.10: Trends of Others in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 4.11: Forecast for Others in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Adoptive Cellular Immunotherapy Market by End Use
  • Table 5.2: Market Size and CAGR of Various End Use in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various End Use in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 5.4: Trends of Hospitals in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 5.5: Forecast for Hospitals in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 5.6: Trends of Cancer Institutes in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 5.7: Forecast for Cancer Institutes in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 5.8: Trends of Others in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 5.9: Forecast for Others in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 7.1: Trends of the North American Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 7.2: Forecast for the North American Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various type in the North American Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various type in the North American Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various end use in the North American Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various end use in the North American Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 8.1: Trends of the European Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 8.2: Forecast for the European Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various type in the European Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various type in the European Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various end use in the European Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various end use in the European Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 9.1: Trends of the APAC Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 9.2: Forecast for the APAC Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various type in the APAC Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various type in the APAC Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various end use in the APAC Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various end use in the APAC Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 10.1: Trends of the ROW Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 10.2: Forecast for the ROW Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various type in the ROW Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various type in the ROW Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various end use in the ROW Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various end use in the ROW Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 11.1: Product Mapping of Adoptive Cellular Immunotherapy Suppliers Based on Segments
  • Table 11.2: Operational Integration of Adoptive Cellular Immunotherapy Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Adoptive Cellular Immunotherapy Revenue
  • Table 12.1: New Product Launches by Major Adoptive Cellular Immunotherapy Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Adoptive Cellular Immunotherapy Market